Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Sutro Biopharma Inc (NASDAQ: STRO) closed the day trading at $3.63 down -3.71% from the previous closing price of $3.77. In other words, the price has decreased by -$3.71 from its previous closing price. On the day, 0.52 million shares were traded. STRO stock price reached its highest trading level at $3.8 during the session, while it also had its lowest trading level at $3.55.
Ratios:
For a better understanding of STRO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.50. In the meantime, Its Debt-to-Equity ratio is 1.22 whereas as Long-Term Debt/Eq ratio is at 1.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on November 09, 2023, initiated with a Buy rating and assigned the stock a target price of $12.
On October 06, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $10.
Wells Fargo Downgraded its Overweight to Equal Weight on March 21, 2023, whereas the target price for the stock was revised from $15 to $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 29 ’24 when Vasquez Nicki sold 12,185 shares for $5.00 per share. The transaction valued at 60,925 led to the insider holds 12,803 shares of the business.
Shtylla Brunilda sold 15,428 shares of STRO for $72,595 on Aug 28 ’23. The Chief Business Officer now owns 0 shares after completing the transaction at $4.71 per share. On Aug 25 ’23, another insider, Shtylla Brunilda, who serves as the Chief Business Officer of the company, sold 11,613 shares for $4.59 each. As a result, the insider received 53,282 and left with 12,928 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, STRO now has a Market Capitalization of 279222176 and an Enterprise Value of -115318672. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.82 while its Price-to-Book (P/B) ratio in mrq is 1.48. Its current Enterprise Value per Revenue stands at -0.75 whereas that against EBITDA is 1.398.
Stock Price History:
The Beta on a monthly basis for STRO is 1.09, which has changed by -0.21086955 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, STRO has reached a high of $6.13, while it has fallen to a 52-week low of $2.01. The 50-Day Moving Average of the stock is -18.98%, while the 200-Day Moving Average is calculated to be -9.49%.
Shares Statistics:
Over the past 3-months, STRO traded about 1.00M shares per day on average, while over the past 10 days, STRO traded about 935910 shares per day. A total of 76.92M shares are outstanding, with a floating share count of 73.77M. Insiders hold about 4.09% of the company’s shares, while institutions hold 80.26% stake in the company. Shares short for STRO as of 1711584000 were 2411685 with a Short Ratio of 2.40, compared to 1709164800 on 2408029. Therefore, it implies a Short% of Shares Outstanding of 2411685 and a Short% of Float of 3.9100002000000003.
Earnings Estimates
Investors are keenly observing as 9 analysts analyze and rate the current performance of Sutro Biopharma Inc (STRO) in the stock market.On average, analysts expect EPS of -$0.92 for the current quarter, with a high estimate of -$0.72 and a low estimate of -$1.09, while EPS last year was -$0.85. The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.03 and low estimates of -$1.08.
Analysts are recommending an EPS of between -$0.76 and -$4.33 for the fiscal current year, implying an average EPS of -$3.3. EPS for the following year is -$3.26, with 10 analysts recommending between -$0.74 and -$5.05.
Revenue Estimates
9 analysts predict $11.92M in revenue for the current quarter. It ranges from a high estimate of $24.65M to a low estimate of $5M. As of the current estimate, Sutro Biopharma Inc’s year-ago sales were $12.67M, an estimated decrease of -5.90% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $22.51M, an increase of 116.20% over than the figure of -$5.90% in the same quarter last year. There is a high estimate of $69.27M for the next quarter, whereas the lowest estimate is $5.2M.
A total of 9 analysts have provided revenue estimates for STRO’s current fiscal year. The highest revenue estimate was $129.61M, while the lowest revenue estimate was $24M, resulting in an average revenue estimate of $55.83M. In the same quarter a year ago, actual revenue was $153.73M, down -63.70% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $73.54M in the next fiscal year. The high estimate is $204.86M and the low estimate is $24M. The average revenue growth estimate for next year is up 31.70% from the average revenue estimate for this year.
